Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial.

Wen-Huan FengWei ChenShan JiangLiying DuDa-Long Zhu

Published in: Diabetes, obesity & metabolism (2021)

Once-daily LY IGlar and IGlar, combined with OAMs, provide effective and similar glycaemic control with comparable safety profiles in insulin-naive Chinese patients with T2D.

Keyphrases

open label
phase iii
type diabetes
glycemic control
phase ii
double blind
clinical trial
phase ii study
placebo controlled
study protocol
insulin resistance
physical activity
weight loss
skeletal muscle
metabolic syndrome
squamous cell carcinoma
adipose tissue